{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-021564","form_type":"8-K","ticker":"KURA","cik":"0001422143","company_name":"Kura Oncology, Inc.","filed_at":"2022-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.599930+00:00","generated_at":"2026-06-22T08:38:10.897494+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Kura Oncology Q3 net loss $35.5M; $150M financing; ziftomenib data at ASH","bullets":["Q3 net loss $35.5M vs $33.4M YoY; R&D expense $25.0M, G&A $11.6M.","Cash, equivalents & short-term investments $427.8M pro forma $462.8M after $25M BMS equity and $10M Hercules draw.","$125M Hercules term loan: $10M drawn immediately, up to $115M additional upon milestones; runway into 2026.","Updated ziftomenib Phase 1 data from KOMET-001 accepted for oral presentation at ASH Dec 10, 2022.","AIM-HN registration trial of tipifarnib in HRAS mutant HNSCC closed to enrollment; KURRENT-LUNG trial initiated."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-021564","json":"https://secwatch.observer/filing/0000950170-22-021564.json","markdown":"https://secwatch.observer/filing/0000950170-22-021564.md","text":"https://secwatch.observer/filing/0000950170-22-021564.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1422143/000095017022021564/0000950170-22-021564-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1422143/000095017022021564/kura-20221103.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T08:38:10.897494+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"639b857e08d8ada1c41acaf74623ec366f6507ee","claim":"Kura Oncology, Inc. reported financial results for the third quarter ended September 30, 2022.","evidence_excerpt":"On November 3, 2022, Kura Oncology, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the third quarter ended September 30, 2022 and providing a corporate update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1422143/000095017022021564/0000950170-22-021564-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}